Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oh is it??
Doh..
Never hold this POS overnight and take profits any and EVERY TIME it actually gives you a little short term. Doh...
DD22
Up 20% doh......lol
The whole market is on fire but this POS $CLSN is down...of course
SMFH,
DD22
I'm calling a 4:00PM price of around $2.90, then some more fluctuation trading after hours today.
The run many of us would like to see will be closer to July.
GLTA!
$CLSN
I'm not selling one share. This is just one of those pullback days that happens pretty much with every stock. PPS is low enough to have some flippers and perhaps some stop-loss triggers earlier today kicked in.
I'm not fazed by the dip at all. The bounce off $2.62 and some fluctuations going on right now is not a showstopper.
$CLSN
What an absolute selling off POS...better save what $$ you have in this before it bleeds back below a $1 or join the scum short sellers slowly destroying this everyday now. MFers can all die painfully slow excruciating deaths. Lol
DD22
There should be some support at $2.50 range based on looking at a 5 year chart. At least a lot of money changed hands there over the years so hopefully there are quite a few shareholders holding in that range.
All IMZo,
DD22
The bears and shorts are clearly in control of this now so we’ll see how low they take it before covering and loading back up.
Smfh...
DD22
Chart is broken now with the 20 and 60DMA acting as resistance now so we’ll probably see the $1.70 range before any announcement in July. Hopefully we can find some support in the 2zz somewhere.
I wish we were back in the $2.98-3.01 channel again.
DD22
Lol...a block of 25K shares sold in 1 whack at $2.95. Someone is loading down here in the $2.90-$3.00ish range for sure and that seems unlikely to be a retail trader.
We get a nice little news on Phase 2 Ovation product progressing and here we sit back in the low/mid $2.90zz yet again for another day/week.
Come on MMs let it loose!!! Volume and trades are gonna trickle to a standstill if you don't let it gain some traction. Lol
DD22
I have a substantial position here. Will continue to accumulate on dips through most of June as I anticipate a run up in sp before the July read out. Because of uncertainties surrounding these sort of sub group studies and read outs I will probably take profits before the July review and ride a small position. GEN-1 is the money shot here. All positive data so far but still a little while to go before FDA approval. The surge in volume and increased sp the other week may well be an indicator of good things to come. Good luck to you, my friend. CLSN
Should see a nice move up as we get closer July. That’s my bet.
Shorts are trying their best to keep a lid on this closing @ 3.01 or above. CSers...lol I hope a whale or hedgie buyer comes in here and destroys their azz.
The company gave us a nugget today and hope their is more news in the pipeline next week and weeks that follow.
More importantly I’m rooting like hell for the company to make progress towards finding an effective treatment or cure for liver cancer. I just lost a brother to that awful “C” disease in January. He wasn’t a drinker and didn’t have cirrhosis. They could help so many people worldwide if they are successful.
All IMO,
DD22
$CLSN
I am new here but loading $CLSN and will do my share of buying into the ASK as well! Not looking to flip $CLSN. I agree it's annoying to be in any stock going sideways in the channel.
GLTY
$CLSN
The $CLSN news seemed to only help the flippers and sellers this morning by giving them some volume and volatility to sell into. Hopefully $CLSN will see the $5 range or more on the run up to the release of results for the Phase 2 in July.
$CLSN staying above the $3 range seems to be a huge area of resistance for the stock and is a critical PPS to break and hold once and for all if we are to see any healthy move into July.
I'm tired of seeing $2.98-$3.00 on the $CLSN Bid/Ask for whole days at a time on Level II. It's like FFS how many shares can $CLSN trade hands in a .3-.6 range on a stock?? LOl
Have a great day and and awesome weekend.
DD22
$CLSN
p.s. I put $CLSN ticker a lot in the message to help us trend higher on the I-Hub Message Board ratings.
PPS should get a lift today. As you can see some decent news came out. Yea, the flippers will be gone when we move up in PPS.
We could see 5 bucks or higher before July.
$CLSN
Maybe when the numbnuts who just absolutely must sell around $3.00-3.03 (bidwhack the whole time too btw) get TF outta the way we can run again.
The good news though is that A LOT OF SHARES are being bought in that range too and will hold for higher gains into the 3zz and hopefully 4zz.
All IMO,
DD22
Had to go up on the bid. Officially in this now. Many good posts here from some that seem to know what they are talking about. Lets make some money!
The risk is still here, I was focusing on worst case
before, the science is very sound and the subgroup data of
285 patients with clear cut of 45+ min RFA + OS endpoint
is also very compelling, I do have a plan to hedge saftly
this time, I bought double number shares Friday and Monday
right after earning's CC, and sold half today, got the rest
free for the second look results now, CLSN is going up early
and fast than I thought, expecting CLSN at 3.50 to 3.80
by end of June, if street smells a stop for efficacy, we
may see 4.5 to 5 right before topline PR on week of July
6, IMO.
Ok glad you satisfied your concern Im still in .
Exactly!
Time will tell, I will get some if my bid hits, if not... so be it.
GLTY!
Thanks.
This is prolly going to fill that gap from this morning. I may move the bid up before after hours kicks in. A friend of mine told me about this one and from what I see, the speculative risk here has potential to turn into decent ROI.
Not flipping it, looking to fill and hold it!
$CLSN
I bought back, if OPTIMA is close to subgroup
data, second look has to stop for efficacy. The
OPTIMA 42 month blended PFS cross down below
the subgroup's PFS KM curve is telling me the
OPTIMA final 197 event OS curves are very narrow
or wild open at the tail end, it means if wild open,
OPTIMA is performing better than the subgroup and
efficacy should shown up at second look, IMO.
Are you in or still out?
This got my attention and hope to fill my order this morning. A good week is always a great thing (even if it's just a 4 day week).
$CLSN
Going to be a good week $$$$
That a boy Clay!! I find your content to be straight forward and honest. I've been following clsn for many years looks like they are near the goal line. Lots of institional owners here that have begun to pile on. Take care bro
Looks to me like it’s gonna be a steady climb$$$$$
* * $CLSN Video Chart 05-22-2020 * *
Link to Video - click here to watch the technical chart video
No pump in site. Can't see any push buy anyone on this play.
So much volume think pump and dump whales accumulate over 10 days not 2 days lol
CLSN Bio Play continues up. Now 3.16 +34%. Closed yesterday at 2.35. Was 1.26 Monday morning. Volume has gone from around 200k daily to 19 million so far today. 7 million yesterday. Entire OS has been traded the last 3 sessions. 29 million OS. All this with no company update or pump. Could be insiders accumulating? Worth a look.
Stop believing everything you read on the internet...
Reputation as manipulator????
* * $CLSN Video Chart 05-21-2020 * *
Link to Video - click here to watch the technical chart video
CLSN is a BIO play one might be interested in. Had ER report last Friday morning and no pps movement to speak of until Tues morning. Been up nicely since with no new updates or pumping. Just maybe insider buys on what they may know. Now 2.12 +23% with good volume.
Celsion Corporation, Inst Holders, 1Q 2020 (CLSN)
4/22/20, 03:26
The following table shows the largest shareholders in CELSION CORP COM (CLSN) for the quarter ended March 31, 2020, listed by holding size. The list represents up to 50 of the largest holders in the company.
Note: Unless otherwise mentioned the reporting date is 03/31/2020
Institution Shares Shares % Last
Held Changed Held Report
The Vanguard Group Inc. 733,268 0 2.506 12/31
BlackRock Fund Advisors 139,172 (524) 0.476 12/31
Renaissance Technologies LLC 79,643 62,722 0.272 12/31
Sabby Capital LLC 68,560 (87,540) 0.234 12/31
Geode Capital Management LLC 64,684 0 0.221 12/31
T. Rowe Price Associates Inc. 60,207 0 0.206 12/31
Northern Trust Investments In 34,281 3,056 0.117 12/31
Dillon & Associates Inc. 22,353 0 0.076 12/31
Dimensional Fund Advisors LP 18,943 0 0.065 12/31
Citadel Advisors LLC 12,439 (20,146) 0.043 12/31
BlackRock Investment Managemen 3,754 0 0.013 12/31
UBS Financial Services Inc. 3,721 (268) 0.013 12/31
JPMorgan Securities LLC (Inves 3,700 3,700 0.013 12/31
UBS Securities LLC 3,000 3,000 0.010 12/31
Gradient Investments LLC 1,000 0 0.003 03/31
Sugarloaf Wealth Management LL 500 200 0.002 03/31
KMS Financial Services Inc. 447 0 0.002 12/31
Morgan Stanley Smith Barney LL 444 0 0.002 12/31
Simplex Trading LLC 138 69 0.000 12/31
Wells Fargo Clearing Services 109 2 0.000 12/31
Morgan Stanley & Co. LLC 100 35 0.000 12/31
ProEquities Inc. 82 0 0.000 12/31
Bank of America NA (Private B 57 0 0.000 12/31
Carroll Financial Associates 40 0 0.000 03/31
Royal Alliance Associates Inc 35 0 0.000 12/31
Rehmann Capital Advisory Group 31 0 0.000 09/30
Triad Hybrid Solutions LLC 15 0 0.000 12/31
US Bancorp Asset Management I 5 5 0.000 12/31
SignatureFD LLC 3 0 0.000 12/31
Riggs Asset Management Co. In 2 0 0.000 12/31
RBC Dominion Securities Inc. 1 (492) 0.000 12/31
CWM LLC 1 0 0.000 12/31
Victory Capital Management In 0 (3,686) 0.000 12/31
CapFinancial Partners LLC 0 (33) 0.000 12/31
Susquehanna Financial Group LL 0 (19,900) 0.000 12/31
The second interim is based on the 158th death in the trial group.
From today's PR
LAWRENCEVILLE, N.J., April 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development
company, announces that the prescribed minimum number of events of 158 patient deaths has been reached for the second pre-specified interim
analysis of the OPTIMA Phase III Study with ThermoDox® plus RFA (radiofrequency ablation) in patients with hepatocellular carcinoma (HCC), or primary liver cancer. Following preparation of the data, the Independent Data Monitoring Committee (iDMC) is expected to meet in July to conduct the
second interim analysis. Celsion expects to announce iDMC recommendations as soon as possible after the meeting.
If this is event is based on 139th event why add to 159?
Celsion I believe started in CC Covid will not impact study.
Does anyone have a handle on monthly enrollments in the study?
Would be nice to put a spreadsheet together to see if the OS looks to be improved.
Wonder if Covid-19 has had any impact...that would not be good.
Did you watch the YouTube video on Dr.Needham? Very informative covers the basics of the drug.
Ahhh, thanks for that.
Appreciate that info.
The FDA in the design trial specified that the doctor would determine heating time...and various types of RFA heating machines were used.
Agree, after all they are replicating the subgroup of their earlier trial.
As far as the management team: there doesn't seem to be a lot of trust developed by them towards the 'Street'.
I see two ways to play this... sell into the pop...
Hold for long term...who buys it, or do they transition to a sales team...
Thot of previous trial, they found after it was complete, and a fail that the dosing for 40 minutes was the key.
How did they not indicate a length of dose in the trial protocol?
That is a severely damaging oversight...
I have no medical training, and good thing for the rest of the world.
I think its moving in the direction of a successful trial if we hear no news on 158th event this month I think its hinting to something successful.
Followers
|
255
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
16750
|
Created
|
08/02/09
|
Type
|
Free
|
Moderators |
Celsion is now funding branded oncology drug development through a fastest-path-to-commercialization strategy for ThermoDox®, its proprietary thermally sensitive liposomal encapsulation of doxorubicin. We are also identifying opportunities to expand our range of therapeutic indications through investments in our core technology platform.
To maximize global commercialization following approval, Celsion is developing distribution alliance opportunities for ThermoDox in key geographic markets. Once these are finalized we will seek to acquire additional platform technology and chemotherapeutic candidates to add to our development pipeline.
Celsion will continue to strengthen its prospects for the future through its research, license and commercialization agreements with leading institutions, among others; the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic and the North Shore Long Island Jewish Health System.
CHART:
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |